NMRANEUMORA THERAPEUTICS, INC.Small cap · $296.5M · FY ending 2025-12-31
$1.60-4.76% · 2026-07-13 · EOD
31/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality—
margins & F-ScoreValue37
valuation vs its own rangeMomentum39
death · price below 200-daySmart Money18
selling · 0 funds · 0P/4S insidersBearish stackDeath crossBelow 200-day
vs S&P 500-40.0%
6-mo excess Trailing performance1M +0.0%
3M -21.6%
6M -31.3%
YTD -3.6%
1Y +50.9%
Not enough profitable-period data to value NMRA on earnings.
ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of ~21%. Annual figures from SEC XBRL.
Net selling0P / 4S insiders · 0 funds hold · 0 Congress buys
Recent insidersMilligan Michael Lee · See RemarksSELL$5,119
BERNS PAUL L · See RemarksSELL$34,459
Pinto Joshua · PresidentSELL$21,093
Aurora Daljit Singh · See RemarksSELL$21,917
Fhealth · 20/100
May need capital~9 months of cash left — burning $51.6M / quarter
- ●Short cash runway Burning cash with roughly 9 months of runway — a dilutive raise looks likely.
- ●One-sided insider selling 4 insider sales and no open-market buys in the recent window.
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.